Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Maxiron is a hematinic combination therapy developed and marketed by Sam Pharmaceutical Ltd. in Nigeria. It is formulated to treat and prevent iron deficiency anemia and to provide nutritional support during periods of increased demand, such as pregnancy and lactation. The product typically contains a combination of **ferrous fumarate** (a source of elemental iron), **folic acid**, and **vitamin B12** (cyanocobalamin). These components work synergistically to support the production of hemoglobin and the maturation of red blood cells. As a branded generic, Maxiron is widely utilized in primary care and obstetric settings across West Africa to manage nutritional deficiencies and general debility.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Maxiron.